FDA approves Simtriyo for treating ADHD in children and adults
MedicalXpress
|
七月 30, 2026
The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗